...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith A Loser Too

Trying to move this Zenith discussion from RVX board to here.

GP posted – 1.50 USD w/o warrants to a strategic partner with some amendment to the licensing deal, I dont think there's much of a haircut on that deal. Anyways, its only 3.3M shares.

I then posted -

GP – “I agree that the $1.50 isn't that bad when you consider that we had to give up an extra 833,334 shares to get US$5 million but in a future deal, it might have saved 3,333,334 shares more dilution at that time from exercised warrants. I will have to get a better handle on the effects of the license deal amendment.

Proceed from here if we wish.

Share
New Message
Please login to post a reply